Cargando…

GRP78 autoantibodies initiate the breakdown of the blood-brain barrier in neuromyelitis optica

Detalles Bibliográficos
Autores principales:	Shimizu, Fumitaka, Ransohoff, Richard M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739724/ https://www.ncbi.nlm.nih.gov/pubmed/29290939 http://dx.doi.org/10.18632/oncotarget.22589

Ejemplares similares

GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica
por: Shimizu, Fumitaka, et al.
Publicado: (2019)

Paraneoplastic Neuromyelitis Optica Spectrum Disorder Related to Glucose-regulated Protein 78 (GRP78) Autoantibodies in a Patient with Lynch Syndrome-associated Colorectal Cancer
por: Minomo, Shogo, et al.
Publicado: (2022)

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016)

GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder
por: Shimizu, Fumitaka, et al.
Publicado: (2021)

Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica
por: Shimizu, Fumitaka, et al.
Publicado: (2015)

Ependyma: a new target for autoantibodies in neuromyelitis optica?
por: Bigotte, Maxime, et al.
Publicado: (2022)

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
por: Asgari, Nasrin, et al.
Publicado: (2017)

Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders
por: Tzartos, John S., et al.
Publicado: (2013)

Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus
por: Sepulveda, Maria, et al.
Publicado: (2019)

Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases
por: Gonzalez-Gronow, Mario, et al.
Publicado: (2022)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Profile of neuromyelitis optica and spectrum disorders in an Indian cohort
por: Koudriavtseva, Tatiana, et al.
Publicado: (2015)

Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders
por: Levy, Michael
Publicado: (2018)

Blood-Brain Barrier Breakdown and Blood-Brain Communication in Neurological and Psychiatric Diseases
por: Friedman, Alon, et al.
Publicado: (2011)

Detection of anti-aquaporin-4 autoantibodies in the sera of Chinese neuromyelitis optica patients★
por: Li, Miao, et al.
Publicado: (2013)

Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica
por: Chanson, Jean-Baptiste, et al.
Publicado: (2013)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Neuromyelitis optica and neuroregeneration
Publicado: (2012)

Immunotherapy of Neuromyelitis Optica
por: Bienia, Benjamin, et al.
Publicado: (2013)

Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?
por: Yamamura, Takashi, et al.
Publicado: (2017)

GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells
por: Ibanez, Jorge, et al.
Publicado: (2023)

Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder
por: Kim, Woojun, et al.
Publicado: (2012)

Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity
por: Pisani, Francesco, et al.
Publicado: (2013)

Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid
por: Marignier, R., et al.
Publicado: (2016)

Spatiotemporal Expression of GRP78 in the Blood Vessels of Rats Treated With 3-Nitropropionic Acid Correlates With Blood–Brain Barrier Disruption
por: Jin, Xuyan, et al.
Publicado: (2018)

GRP78 in lung cancer
por: Xia, Shengkai, et al.
Publicado: (2021)

Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2017)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico
por: Zarei, Sara, et al.
Publicado: (2018)

GRP78 is a novel receptor initiating a vascular barrier protective response to oxidized phospholipids
por: Birukova, Anna A., et al.
Publicado: (2014)

Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2020)

New Insights into Neuromyelitis Optica
por: Kim, Woojun, et al.
Publicado: (2011)

Experimental Models of Neuromyelitis Optica
por: Bradl, Monika, et al.
Publicado: (2013)

Molecular Pathogenesis of Neuromyelitis Optica
por: Bukhari, Wajih, et al.
Publicado: (2012)

B lymphocytes in neuromyelitis optica
por: Bennett, Jeffrey L., et al.
Publicado: (2015)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Multisystem involvement in neuromyelitis optica
por: Langille, Megan M., et al.
Publicado: (2015)

A Case of Neuromyelitis Optica
por: DE, M. N., et al.
Publicado: (1946)

A Case of Neuromyelitis Optica
por: Shone, S.
Publicado: (1940)

Cannot write session to /tmp/vufind_sessions/sess_td42esef1612aj48q7g2nq4o76